PT-杂志文章AU-瓦伦，Ciaran au -Strand，Lauren au- Hayes，Hayes，Jennifer au -Kadura，Suha Au -Collins，Bridget Au -Ho -Ho -Ho -ho -ho -spada，Carolyn au -Carolyn au -Canestaro -Canestaro，Will Au -Kolb，Martin Au，Martin Au-Raghu，Ganesh Ti-肺纤维化的R量表（PF）：一种评估与健康相关的生活质量援助评估的简单，视觉工具-10.1183/13993003.00917-2021 DP-2021 DP -2021 JAN 01 TA-欧洲呼吸杂志PG- PG - PG-- PG-- pg-- pg-- pg---2100917 4099 - //www.qdcxjkg.com/content/early/2021/05/28/13993003.00917-2021.short 4100 - //www.qdcxjkg.com/content/early/2021/05/28/13993003.00917-2021.Full AB-特发性肺纤维化（IPF）经历与健康相关生活质量受损（HRQOL）的经验。已经开发了几种工具来客观地评估该患者人群中的HRQOL，但在常规临床实践中没有使用。目标是开发一种快速，特定的工具，可在常规诊所访问期间用于IPF患者，以一种新颖而简单的方式用于IPF。开发了5项数值评级量表（NRS），并将其与其他两个先前验证的工具进行了比较。招募了在ILD中心管理的100例IPF患者，以完成R级PF，国王短暂的间隙肺病问卷（K-BILD）和EUROOQOL 5维5级问卷（EQ-5DD-5 l）除了肺功能和6分钟的步行测试外，所有100名患者的测量和主要结果成功完成了三种HRQOL工具，其中53个患者在随访时再次完成它们。内部一致性很高（Cronbach的α0.825），地板/天花板效果最小。与K-Bild（r = -0.713）和EQ-5D-5 L（r = -0.665）相比，R级PF的并发有效性中等至高。并发有效性与生理措施相比（强迫生命力，r = -0.307，6分钟步行距离，r = -0.383）。当比较各个疾病严重程度的分数时，R级PF表现出良好的已知组有效性。CONCONCLUSIONSR-SCALE-PF与K-BILD和EQ-5D-5 L.相关。 NRS tool subject to validation in patients from other centers will provide the opportunity to objectively measure HRQoL in routine clinical practice for patients with IPF.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Scallan has nothing to disclose.Conflict of interest: Dr. Strand has nothing to disclose.Conflict of interest: Dr. Hayes has nothing to disclose.Conflict of interest: Dr. Kadura has nothing to disclose.Conflict of interest: Dr. Collins reports personal fees from Boehringer Ingelheim, outside the submitted work; .Conflict of interest: Dr. Ho has nothing to disclose.Conflict of interest: Dr. Spada has nothing to disclose.Conflict of interest: Dr. Canestaro has nothing to disclose.Conflict of interest: Dr. Kolb reports grants from Canadian Pulmonary Fibrosis Foundation, other from Roche, other from Boehringer Ingelheim, grants from Canadian Institute for Health Research, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, grants and personal fees from Liminal, other from European Respiratory Journal, personal fees from Third Pole, personal fees from MitoImmune, grants and personal fees from Pieris, personal fees from Abbvie, personal fees from DevPro Biopharma, personal fees from Horizon, personal fees from Algernon, personal fees from CSL Behring, outside the submitted work; .Conflict of interest: Dr. Raghu has nothing to disclose.